Ioglycamate is triiodocarboxyanilide derivative patented by Schering A.-G. as intravenous cholangiographic X-ray contrast media. Meglumine ioglycamate and was marketed in South Africa in 1976 under brand name Biligram. Ioglycamate is rapidly eliminated from human blood where approximately 95% of the administered dose is bound to the plasma proteins. The mean plasma half-life is 30 minutes. Tbe compound is not metabolised to any great extent but most is eliminated a unchanged molecules with the faeces. In clinical trials good to excellent opacification was achieved in 69% of all patients. A total of 17% of all patients showed side-effects, the majority of which were transient and of a minor nature. Blood pressure and liver function were apparently not affected